Alvotech (ALVO)
ALVONASDAQ-GMBiotechnology: Biological Products (No Diagnostic Substances)
$4.88
+0.1900 (+4.05%) today
At the close, Nov 10, 4:00 PM ET. After hours $4.89 +0.20%
- Market cap
- $1.91bn
- P/E
- –
- EPS, last 4 quarters
- $-0.5900
- Dividend yield
- –
- Day range
- $4.66 to $4.89
- 52-week range
- $2.94 to $6.53
- Average volume
- 1.03m
- Previous close
- $4.69
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $7.67, +57.2% from here
Earnings
next estimate $-0.0100Next report Nov 11, 2026
Sep 2025
-140.0%
Dec 2025
-384.6%
Mar 2026
-28.6%
Jun 2026
-83.3%
estimate reported, and the surprise
Financials
No quarterly figures from the source.
News
8 latest- Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue EstimatesZacks · 1 day ago
- Vericel Corporation (VCEL) Beats Q3 Earnings and Revenue EstimatesZacks · 5 days ago
- Will Alvotech (ALVO) Report Negative Earnings Next Week? What You Should KnowZacks · 6 days ago
- Repligen (RGEN) Q3 Earnings and Revenues Surpass EstimatesZacks · Oct 27, 2026
- Weekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial Win RTTNews · Oct 23, 2026
- New Strong Sell Stocks for October 21stZacks · Oct 21, 2026
- New Strong Sell Stocks for October 20thZacks · Oct 21, 2026
- FDA Clears New Manufacturing Process For Alvotech's SIMLANDI Biosimilar; Stock Up RTTNews · Oct 20, 2026
The company
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira (adalimumab), Stelara (ustekinumab), Simponi (golimumab), Eylea (aflibercept) and Prolia/Xgeva (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GM
- Region
- Europe
- Website
- alvotech.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.